The Motley Fool··Sarah SidlowMaze Therapeutics CSBO Sells $190K in Stock Despite Strong Trial Data
Maze Therapeutics CSBO Atul Dandekar sold 7,500 shares for $190,000 under a pre-planned trading agreement, concurrent with positive phase 2 trial results.
MAZEclinical-stage biotechprecision medicine